Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

ABSTRACT:

Background

RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

Methods

We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.

Results

In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previou

SUBMITTER: Drilon A 

PROVIDER: S-EPMC7506467 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature